-transparent.png){kind=logo}
The effect of 16,16-dimethyl prostaglandin E2 (DmPGE2), in doses subthreshold for antisecretory activity, were examined in female rats. The aims were to determine if DmPGE2 alters the disposition of acetylsalicylic acid (ASA) within the gastric mucosa and if DmPGE2 could attenuate the ulcerogenic effect of oral ASA. Gastric lesions occurred after an oral, but not an intravenous dose of 150 mg/kg ASA. Lesions could be prevented by pretreatment with 5 micrograms/kg DmPGE2 orally 30 min prior to ASA. DmPGE2 elevated fundic concentrations of both ASA and salicylic acid (SA) within the first hour when ASA was given orally. The ratio of the concentration of ASA/SA in fundus was not changed, indicating that DmPGE2 did not depress the fundic esterase activity. It is concluded that the cytoprotective effect of DmPGE2 is not related to a change in mucosal concentration or elimination of ASA or SA.
U Weissenborn, and
S Maedge, and
K F Sewing
June 1979,
Gut,
U Weissenborn, and
S Maedge, and
K F Sewing
March 1997,
Digestive diseases and sciences,
U Weissenborn, and
S Maedge, and
K F Sewing
January 1987,
Virchows Archiv. A, Pathological anatomy and histopathology,
U Weissenborn, and
S Maedge, and
K F Sewing
January 1981,
Prostaglandins,
U Weissenborn, and
S Maedge, and
K F Sewing
July 1986,
Acta physiologica Scandinavica,
U Weissenborn, and
S Maedge, and
K F Sewing
January 1981,
Deutsche medizinische Wochenschrift (1946),
U Weissenborn, and
S Maedge, and
K F Sewing
January 1993,
Gastroenterology,
U Weissenborn, and
S Maedge, and
K F Sewing
September 1977,
British journal of pharmacology,
U Weissenborn, and
S Maedge, and
K F Sewing
March 1982,
British journal of clinical pharmacology,
U Weissenborn, and
S Maedge, and
K F Sewing
October 1987,
The Journal of laboratory and clinical medicine,
